Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of KN026 + HB1801 versus trastuzumab + pertuzumab + docetaxel for first-line HER2-positive recurrent or metastatic breast cancer
CTR20231442Phase 3Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Jul 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of anbenitamab, albumin-bound docetaxel in breast cancer, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Jul 2023; status: active.
02
Drugs
anbenitamabalbumin-bound docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20231442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231442.